| Title: |
GLP-1 Receptor Agonist Use and Risk of Suicide Death |
| Authors: |
Ueda, Peter; Söderling, Jonas; Wintzell, Viktor; Svanström, Henrik; Pazzagli, Laura; Eliasson, Björn; Melbye, Mads; Hviid, Anders; Pasternak, Björn |
| Source: |
Ueda , P , Söderling , J , Wintzell , V , Svanström , H , Pazzagli , L , Eliasson , B , Melbye , M , Hviid , A & Pasternak , B 2024 , ' GLP-1 Receptor Agonist Use and Risk of Suicide Death ' , JAMA Internal Medicine , vol. 184 , no. 11 , pp. 1301-1312 . https://doi.org/10.1001/jamainternmed.2024.4369 |
| Publication Year: |
2024 |
| Collection: |
University of Copenhagen: Research / Forskning ved Københavns Universitet |
| Description: |
IMPORTANCE Concerns have been raised regarding a link between use of glucagon-like peptide-1 (GLP-1) receptor agonists and increased risk of suicidality and self-harm. OBJECTIVE To assess the association between use of GLP-1 receptor agonists and the risk of suicide death in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS This active-comparator new-user cohort study used nationwide register data from Sweden and Denmark from 2013 to 2021. Adults 18 to 84 years old who initiated treatment with GLP-1 receptor agonists or the comparator sodium-glucose cotransporter-2 (SGLT2) inhibitors were included. Data were analyzed from March to June 2024. EXPOSURE Initiation of treatment with a GLP-1 receptor agonist or SGLT2 inhibitor. MAIN OUTCOMES AND MEASURES The primary outcome was suicide death recorded in the cause of death registers. Secondary outcomes were the composite of suicide death and nonfatal self-harm and the composite of incident depression and anxiety-related disorders. Using propensity score weighting, hazard ratios (HRs) with 95% CIs were calculated separately in the 2 countries and pooled in a meta-analysis. RESULTS In total, 124 517 adults initiated a GLP-1 receptor agonist and 174 036 initiated an SGLT2 inhibitor; among GLP-1 receptor agonist users, the mean (SD) age was 60 (13) years, and 45% were women. During a mean (SD) follow-up of 2.5 (1.7) years, 77 suicide deaths occurred among users of GLP-1 receptor agonists and 71 suicide deaths occurred among users of SGLT2 inhibitors: weighted incidences were 0.23 vs 0.18 events per 1000 person-years (HR, 1.25; 95% CI, 0.83-1.88), with an absolute difference of 0.05 (95% CI, −0.03 to 0.16) events per 1000 person-years. The HR was 0.83 (95% CI, 0.70-0.97) for suicide death and nonfatal self-harm, and the HR was 1.01 (95% CI, 0.97-1.06) for incident depression and anxiety-related disorders. CONCLUSIONS AND RELEVANCE This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of GLP-1 receptor ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| DOI: |
10.1001/jamainternmed.2024.4369 |
| Availability: |
https://researchprofiles.ku.dk/da/publications/b034221f-d141-4e2c-83b3-091da929ffd1; https://doi.org/10.1001/jamainternmed.2024.4369; https://curis.ku.dk/ws/files/405019476/jamainternal_ueda_2024_oi_240055_1724698371.32795.pdf |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.710EAB20 |
| Database: |
BASE |